Report Overview

Global Cancer Biomarkers Market Forecast and Trends

Global Cancer Biomarkers market has reached 13.065 Billion in 2019 and is estimated to reach USD 29.45 Billion in 2026 and might grow by CAGR of 12.61% during the forecast period 2020-2026. The growth of the market is upheld by the surging prevalence of cancer, coupled with the rising awareness about the usage of biomarkers at several stages of cancer. Lack of physical activities, frequent sun & U.V. exposure, improper diet, and growing tobacco consumption are essential factors attributed to cancer's escalating prevalence. Around 22% of cancer deaths are caused due to tobacco consumption and are regarded as the principal risk factor for cancer. Besides, few internal factors such as hormonal imbalance, genetic mutation, and metabolic mutation contribute to the surge in cancer cases, increasing cancer biomarkers' demand.

Moreover, the rising demand for clinical diagnosis in cancer's early stages and growing geriatric population base further propel cancer biomarkers' usage rates. Surging utilization of the biomarkers in surrogate endpoints & drug targets developments, increasing interest among researchers & students regarding cancer diagnostic researchers are few crucial success factors for the growth of the global cancer biomarkers market.

Global Cancer Biomarkers Market Overview:

Cancer biomarkers are chemicals that are released during the presence of a tumor, or a clear indicator of cancer in the body. These are either a liquid, a molecule, or a physical occurrence that indicates cancerous cells. These molecules are typically found in urine, tissues, blood, serum, and other body fluids that exhibit any unusual disease method. Cancer biomarkers are traceable substances that can be used as a biological tumor status indicator and can assess cancer diagnostic and prognostic levels. Cancer prevention by diagnosing and evaluating various biomarkers of cancer using specific diagnostic techniques is a profound method for achieving rapid treatment outcomes.

Growth drivers

Technological advancements

There have been significant technological developments over diagnostic imaging, immunoassays, omics technologies, and bioinformatics. Omics technology developments allow faster acquisition of proteomic, genomic, and metabolomics data and its alliance with clinical trial data using advanced bioinformatics tools. Over the past decade, the omics movement has growing biomarker applications in biomedical research. Additionally, developments in high-throughput genomic technologies facilitate the identification and analysis of crucial gene mutations and polymorphisms, thereby expanding the spectrum of available genomic biomarkers.

Increased incidence and prevalence of different types of cancer

A surge in cancer cases among the global population has boosted the demand for the Cancer Biomarkers. As per the World Health Organization, it might increase cancer cases over the next two decades. Cancer is mainly prevalent in lower and middle-income nations since they lack suitable healthcare infrastructure to effectively combat the condition. Besides, the cancer cases were higher in men than in women.

Restraints

Technical issues concerning collection and storage of samples

Most epidemiological studies use biomarkers to examine various stages of human disease. It requires careful handling and storage of sensitive biological samples to obtain a great deal of information from small pieces and reduce future research costs using banked samples. Also, risk detection, screening, diagnosis, and monitoring processes require different models. Furthermore, detailed tracking, specimen storage, and recovery software are needed for proper sample handling and management. Such problems might hamper the overall market growth of cancer biomarkers.

Global Cancer Biomarkers Market: Type

Based on Type, the Cancer Biomarkers market segmented into Protein Biomarker, Genetic Biomarker, and Others (cell, viral, and carbohydrate biomarkers). The genetic biomarker segment is forecasted to dominate during the forecast period, owing to technological advancements to detect the mutation. Gene expression profiling (microarray), Next-generation sequencing (NGS), and polymerase chain reaction (PCR) are the essential technologies used for genetic biomarker discovery and diagnosis. Advancements in high-throughput technologies are the major factors driving the cancer biomarkers market.

Global Cancer Biomarkers Market: Cancer Type

Based on Cancer Type, the Cancer Biomarkers market segregated into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Bladder Cancer, Kidney Cancer, and Others. The lung cancer segment is projected to have a higher CAGR during the forecast horizon due to an increased number of new lung cancer cases. The company's growing focus on research on lung cancer biomarkers is another major factor for market growth. The increased understanding of the morphology of lung carcinogenesis, the development of high-throughput techniques for biomarker discovery, and increased focus on early detection of cancer are also thrusting the market growth.

Global Cancer Biomarkers Market: Profiling Technology

Based on Profiling Technology, the Cancer Biomarkers market segmented into Omics Technologies, Imaging Technologies, Immunoassays, Cytogenetics, Bioinformatics, and Others. The bioinformatics segment is predicted to grow at a very high CAGR during the forecast period since it helps identify robust and biomedically significant biomarkers. Data mining also allows tools for interpreting and evaluating the resulting models and predictions and the methods to support the implementation of prophecy explanation mechanisms. Furthermore, technological advancements, an expansion in demand for the development of new drugs and clinical diagnostic tests, and the burgeoning information technology industry in developing nations, such as India and China, drive bioinformatics applications in biomarker discovery development.

Global Cancer Biomarkers Market: Application

Based on Application, the Cancer Biomarkers market segmented into Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment, and Others. The Drug Discovery & Development segment is expected to record the highest CAGR during the forecast period since it facilitates a better understanding of diseases during target discovery. It plays a significant role in guiding decisions in every phase of drug development—from drug discovery and preclinical evaluations to clinical trials. The biomarkers' Application helps confirm drug candidates' efficiency and safety, get their mechanisms of action, and determine an effective dose regime. This is resulting in the growth of this segment.

Global Cancer Biomarkers Market: Regional insights

By geography, the global Cancer Biomarkers Market segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to have the lion's share in the global cancer biomarkers market during the forecast period, owing to the adoption of advanced technologies, increasing the number of research studies to develop novel biomarkers. Many pharmaceutical firms exist, rising funding and investments from public and private organizations, and the growing use of biomarkers in patient stratification and drug development methods.

Cancer Biomarkers Market: Competitive Landscape

The major market players in the Global Cancer Biomarkers are Thermo Fisher Scientific, Bio-Rad Laboratories, Roche Diagnostics, Qiagen N.V., Illumina, G.E. Healthcare, Agilent Technologies, Biomérieux SA, Merck & Co., Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, Myriad Genetics, Sysmex Corporation, Hologic, Quest Diagnostics. Other Prominent Players are expanding their presence in the market by implementing various innovations and technologies.

The objective of the Study:

To analyze and forecast the global Cancer Biomarkers market size of the market in terms of value.

To examine the careful market segmentation and forecast the market size, in terms value, based on the region by segmenting the Global Cancer Biomarkers market into five parts, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa and their leading countries.

To outline, categorized, and forecast the global Cancer Biomarkers market based on Type, Cancer Type, Profiling Technology, and Application.

To examine competitive developments like technological advancement, services, and regulative framework within the global Cancer Biomarkers Market.

To highlight the impact analysis of the factors affecting the market dynamics such as drivers, restraints, opportunities, and challenges.

To strategically profile the key players and comprehensively analyze their market shares and detail the competitive landscape for market leaders.

Scope of the Report:

Attribute	Details
Years Considered	Historical data – 2016-2019
	Base Year – 2019
	Forecast – 2020 – 2026
Facts Covered	Revenue in USD Million/Billion
Market Coverage	U.S, Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Argentina, Japan, South Korea, China, India, UAE, South Africa, Saudi Arabia
Product/Service Segmentation	By Type, Cancer Type, Profiling Technology, and Application
Key Players	Thermo Fisher Scientific, Bio-Rad Laboratories, Roche Diagnostics, Qiagen N.V., Illumina, G.E. Healthcare, Agilent Technologies, Biomérieux SA, Merck & Co., Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, Myriad Genetics, Sysmex Corporation, Hologic, Quest Diagnostics, and other Prominent Players.

 

By Type

·         Protein Biomarker

·         Genetic Biomarker

·         Others (cell, viral, and carbohydrate biomarkers)

By Cancer Type

·         Breast Cancer

·         Lung Cancer

·         Colorectal Cancer

·         Prostate Cancer

·         Thyroid Cancer

·         Bladder Cancer

·         Kidney Cancer

·         Others

By Profiling Technology

·         Omics Technologies

·         Imaging Technologies

·         Immunoassays

·         Cytogenetics

·         Bioinformatics

·         Others

By Application

·         Diagnostics

·         Drug Discovery & Development

·         Prognostics

·         Risk Assessment

·         Others

By Region:

·         Asia Pacific

·         North America

·         Europe

·         Latin America

·         Middle East & Africa

Business Questions answered by the report

How will the market drivers, restraints, and opportunities affect the market dynamics?

What will be the market size in terms of value and volume and market statistics with a detailed classification?

Which segment dominates the market or region, and one will be the fastest-growing, and why?

A comprehensive survey of the competitive landscape and the market participant players

Analysis of strategy adopted by the key player and their impact on other players.

Customization Scope for the Client

Client satisfaction is our first and last priority, and that is why BlueWeave Consulting offers customization according to the company’s specific needs. The following customization options are available for the report:

Additional Company Information

• With five further company detail analysis
• Additional country analysis
• Detailed segment analysis

1.    Research Framework

1.1. Research Objective

1.2. Product Overview

1.3. Market Segmentation

2.    Research Methodology

2.1. Qualitative Research

2.1.1.   Primary & Secondary Sources

2.2. Quantitative Research

2.2.1.   Primary & Secondary Sources

2.3. Breakdown of Primary Research Respondents, By Region

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4. Breakdown of Primary Research Respondents

2.5. Market Size Estimation

2.6. Assumption for The Study

2.7. Market Breakdown & Data Triangulation

3.    Executive Summary

4.    Global Cancer Biomarkers Insights

4.1. DROC Analysis

4.1.1.   Growth Drivers

4.1.2.   Restraints

4.1.3.   Opportunities

4.1.4.   Challenges

4.2. Technological Landscape

4.3. Regulatory Framework

4.4. Company Market Share Analysis, 2019

4.5. Porter’s Five forces analysis

4.5.1.   Bargaining Power of Suppliers

4.5.2.   Bargaining Power of Buyers

4.5.3.   Threat of New Entrants

4.5.4.   Threat of Substitutes

4.5.5.   Intensity of Rivalry

5.    Global Cancer Biomarkers Market Overview

5.1. Market Size & Forecast by Value, 2016-2026

5.1.1.   By Value (USD Billion)

5.2. Market Share & Forecast 2016-2026

5.2.1.   By Type

5.2.1.1.       Protein Biomarker

5.2.1.2.       Genetic Biomarker

5.2.1.3.       Others (cell, viral, and carbohydrate biomarkers)

5.2.2.   By Cancer Type

5.2.2.1.       Breast Cancer

5.2.2.2.       Lung Cancer

5.2.2.3.       Colorectal Cancer

5.2.2.4.       Prostate Cancer

5.2.2.5.       Thyroid Cancer

5.2.2.6.       Bladder Cancer

5.2.2.7.       Kidney Cancer

5.2.2.8.       Others

5.2.3.   By Profiling Technology

5.2.3.1.       Omics Technologies

5.2.3.2.       Imaging Technologies

5.2.3.3.       Immunoassays

5.2.3.4.       Cytogenetics

5.2.3.5.       Bioinformatics

5.2.3.6.       Others

5.2.4.   By Application

5.2.4.1.       Diagnostics

5.2.4.2.       Drug Discovery & Development

5.2.4.3.       Prognostics

5.2.4.4.       Risk Assessment

5.2.4.5.       Others

5.2.5.   By Region

5.2.5.1.       North America

5.2.5.2.       Europe

5.2.5.3.       Asia Pacific

5.2.5.4.       Latin America

5.2.5.5.       Middle East & Africa

6.    North America Cancer Biomarkers Market

6.1. Market Size & Forecast by Value, 2016-2026

6.1.1.   By Value (USD Billion)

6.2. Market Share & Forecast 2016-2026

6.2.1.   By Type

6.2.2.   By Cancer Type

6.2.3.   By Profiling Technology

6.2.4.   By Application

6.2.5.   By Country

6.2.5.1.       U.S

6.2.5.2.       Canada

7.    Europe Cancer Biomarkers Market

7.1. Market Size & Forecast by Value, 2016-2026

7.1.1.   By Value (USD Billion)

7.2. Market Share & Forecast 2016-2026

7.2.1.   By Type

7.2.2.   By Cancer Type

7.2.3.   By Profiling Technology

7.2.4.   By Application

7.2.5.   By Country

7.2.5.1.       Germany

7.2.5.2.       U.K

7.2.5.3.       France

7.2.5.4.       Italy

7.2.5.5.       Rest of Europe

8.    Asia Pacific Cancer Biomarkers Market

8.1. Market Size & Forecast by Value, 2016-2026

8.1.1.   By Value (USD Billion)

8.2. Market Share & Forecast 2016-2026

8.2.1.   By Type

8.2.2.   By Cancer Type

8.2.3.   By Profiling Technology

8.2.4.   By Application

8.2.5.   By Country

8.2.5.1.       China

8.2.5.2.       India

8.2.5.3.       Japan

8.2.5.4.       South Korea

8.2.5.5.       Rest of Asia Pacific

9.    Latin America Cancer Biomarkers Market

9.1. Market Size & Forecast by Value, 2016-2026

9.1.1.   By Value (USD Billion)

9.2. Market Share & Forecast 2016-2026

9.2.1.   By Type

9.2.2.   By Cancer Type

9.2.3.   By Profiling Technology

9.2.4.   By Application

9.2.5.   By Country

9.2.5.1.       Brazil

9.2.5.2.       Mexico

9.2.5.3.       Argentina

9.2.5.4.       Rest of Latin America

10.Middle East & Africa Cancer Biomarkers Market

10.1.             Market Size & Forecast by Value, 2016-2026

10.1.1.                By Value (USD Billion)

10.2.             Market Share & Forecast 2016-2026

10.2.1.                By Type

10.2.2.                By Cancer Type

10.2.3.                By Profiling Technology

10.2.4.                By Application

10.2.5.                By Country

10.2.5.1.    Saudi Arabia

10.2.5.2.    UAE

10.2.5.3.    South Africa

10.2.5.4.    Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

11.1.             Thermo Fisher Scientific

11.2.             Bio-Rad Laboratories

11.3.             Roche Diagnostics

11.4.             Qiagen N.V.

11.5.             Illumina

11.6.             G.E. Healthcare

11.7.             Agilent Technologies

11.8.             Biomérieux SA

11.9.             Merck & Co.

11.10.          Abbott Laboratories

11.11.          Becton, Dickinson, and Company

11.12.          Danaher Corporation

11.13.          Myriad Genetics

11.14.          Sysmex Corporation

11.15.          Hologic

11.16.          Quest Diagnostics

11.17.          Other Prominent Players

 

List of Figures

Fig: Global Cancer Biomarkers Segmentation

Fig: Company Market Share Analysis, 2019

Fig: Global Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Region, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: North America Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: North America Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Europe Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Europe Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Latin America Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Latin America Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Middle East & Africa Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

 

 

List of Tables:

Table: Global Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Region, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Middle East & Africa Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Thermo Fisher Scientific Financial Analysis

Table: Bio-Rad Laboratories Financial Analysis

Table: Roche Diagnostics Financial Analysis

Table: Qiagen N.V. Financial Analysis

Table: G.E. Healthcare Financial Analysis

Table: Agilent Technologies Financial Analysis

Table: Biomérieux SA Financial Analysis

Table: Merck & Co. Financial Analysis

Table: Abbott Laboratories Financial Analysis

Table: Danaher Corporation Financial Analysis

 

*Financial Information of non-listed companies will be provided as per the availability

**The segmentation and the companies are subjected to modification based on in-depth secondary for the final deliverable.